Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 720 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials December 6, 2023 ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 Alex Trebek Admits Undergoing Chemo For Stage 4 Pancreatic Cancer Has... May 15, 2019 Load more HOT NEWS Police Officer Has Bulletproof Vest to Thank for Helping Her Discover... County Denies Immunocompromised Employee’s Request to Work from Home During COVID-19 Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability...
